Amalgamated Bank Purchases 8,660 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Amalgamated Bank grew its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 777.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,774 shares of the company's stock after purchasing an additional 8,660 shares during the quarter. Amalgamated Bank's holdings in TransMedics Group were worth $1,535,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Harbor Capital Advisors Inc. lifted its stake in shares of TransMedics Group by 48.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 8,964 shares of the company's stock valued at $1,407,000 after purchasing an additional 2,916 shares during the period. Farther Finance Advisors LLC lifted its stake in shares of TransMedics Group by 187.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company's stock valued at $76,000 after purchasing an additional 316 shares during the period. New York State Teachers Retirement System acquired a new position in shares of TransMedics Group in the 3rd quarter valued at about $1,217,000. State of Alaska Department of Revenue acquired a new position in TransMedics Group during the 3rd quarter worth approximately $2,560,000. Finally, Louisiana State Employees Retirement System acquired a new position in TransMedics Group during the 3rd quarter worth approximately $2,528,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on TMDX shares. Baird R W raised TransMedics Group to a "strong-buy" rating in a research note on Tuesday, September 24th. Stephens upped their price target on TransMedics Group from $151.00 to $178.00 and gave the stock an "overweight" rating in a research note on Friday, August 2nd. Piper Sandler reaffirmed an "overweight" rating and set a $180.00 price target on shares of TransMedics Group in a research note on Tuesday, October 29th. Canaccord Genuity Group lowered their price objective on TransMedics Group from $169.00 to $109.00 and set a "buy" rating for the company in a research note on Tuesday, October 29th. Finally, Robert W. Baird lowered their price objective on TransMedics Group from $200.00 to $150.00 and set an "outperform" rating for the company in a research note on Tuesday, October 29th. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, TransMedics Group has an average rating of "Buy" and an average price target of $144.80.

Insiders Place Their Bets

In related news, insider Nicholas Corcoran sold 10,000 shares of TransMedics Group stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the transaction, the insider now owns 21,105 shares in the company, valued at $3,714,902.10. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the firm's stock in a transaction on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the sale, the chief executive officer now owns 61,643 shares of the company's stock, valued at $9,457,269.06. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Nicholas Corcoran sold 10,000 shares of the firm's stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the completion of the sale, the insider now directly owns 21,105 shares in the company, valued at approximately $3,714,902.10. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 36,958 shares of company stock valued at $5,230,528 over the last quarter. 7.00% of the stock is owned by corporate insiders.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX traded up $4.29 on Wednesday, hitting $95.70. The company's stock had a trading volume of 1,015,320 shares, compared to its average volume of 957,767. TransMedics Group, Inc. has a 1 year low of $61.98 and a 1 year high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company has a market capitalization of $3.21 billion, a PE ratio of 103.60 and a beta of 2.08. The company has a 50-day simple moving average of $129.09 and a 200 day simple moving average of $139.89.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. During the same period in the previous year, the company earned ($0.12) EPS. TransMedics Group's quarterly revenue was up 63.7% on a year-over-year basis. Sell-side analysts forecast that TransMedics Group, Inc. will post 1.07 EPS for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.